Notice: This company has been marked as potentially delisted and may not be actively trading. Lionheart Acquisition Co. II (LCAP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends LCAP vs. BDSX, AKYA, IPHA, SGHT, ADAP, PBYI, FTLF, VTYX, PVLA, and ARTVShould you be buying Lionheart Acquisition Co. II stock or one of its competitors? The main competitors of Lionheart Acquisition Co. II include Biodesix (BDSX), Akoya Biosciences (AKYA), Innate Pharma (IPHA), Sight Sciences (SGHT), Adaptimmune Therapeutics (ADAP), Puma Biotechnology (PBYI), FitLife Brands (FTLF), Ventyx Biosciences (VTYX), Palvella Therapeutics (PVLA), and Artiva Biotherapeutics (ARTV). These companies are all part of the "medical" sector. Lionheart Acquisition Co. II vs. Biodesix Akoya Biosciences Innate Pharma Sight Sciences Adaptimmune Therapeutics Puma Biotechnology FitLife Brands Ventyx Biosciences Palvella Therapeutics Artiva Biotherapeutics Lionheart Acquisition Co. II (NASDAQ:LCAP) and Biodesix (NASDAQ:BDSX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation, community ranking and media sentiment. Which has more risk & volatility, LCAP or BDSX? Lionheart Acquisition Co. II has a beta of 0.08, indicating that its stock price is 92% less volatile than the S&P 500. Comparatively, Biodesix has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500. Do insiders & institutionals have more ownership in LCAP or BDSX? 21.0% of Biodesix shares are owned by institutional investors. 19.4% of Lionheart Acquisition Co. II shares are owned by insiders. Comparatively, 69.2% of Biodesix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is LCAP or BDSX more profitable? Lionheart Acquisition Co. II has a net margin of 0.00% compared to Biodesix's net margin of -66.84%. Lionheart Acquisition Co. II's return on equity of -44.30% beat Biodesix's return on equity.Company Net Margins Return on Equity Return on Assets Lionheart Acquisition Co. IIN/A -44.30% 1.39% Biodesix -66.84%-275.79%-43.05% Do analysts rate LCAP or BDSX? Biodesix has a consensus price target of $3.06, suggesting a potential upside of 194.23%. Given Biodesix's stronger consensus rating and higher probable upside, analysts clearly believe Biodesix is more favorable than Lionheart Acquisition Co. II.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lionheart Acquisition Co. II 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Biodesix 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer LCAP or BDSX? Biodesix received 29 more outperform votes than Lionheart Acquisition Co. II when rated by MarketBeat users. CompanyUnderperformOutperformLionheart Acquisition Co. IIN/AN/ABiodesixOutperform Votes2974.36% Underperform Votes1025.64% Does the media favor LCAP or BDSX? In the previous week, Biodesix had 2 more articles in the media than Lionheart Acquisition Co. II. MarketBeat recorded 2 mentions for Biodesix and 0 mentions for Lionheart Acquisition Co. II. Biodesix's average media sentiment score of 1.44 beat Lionheart Acquisition Co. II's score of 0.00 indicating that Biodesix is being referred to more favorably in the news media. Company Overall Sentiment Lionheart Acquisition Co. II Neutral Biodesix Positive Which has higher valuation and earnings, LCAP or BDSX? Lionheart Acquisition Co. II has higher earnings, but lower revenue than Biodesix. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLionheart Acquisition Co. IIN/AN/A$3.21MN/AN/ABiodesix$65.56M2.31-$52.15M-$0.39-2.67 SummaryBiodesix beats Lionheart Acquisition Co. II on 10 of the 14 factors compared between the two stocks. Get Lionheart Acquisition Co. II News Delivered to You Automatically Sign up to receive the latest news and ratings for LCAP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LCAP vs. The Competition Export to ExcelMetricLionheart Acquisition Co. IIBusiness Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$34.51M$148.07M$5.61B$9.14BDividend YieldN/AN/A5.36%3.98%P/E RatioN/A105.0089.6917.66Price / SalesN/A34.231,219.4081.09Price / Cash20.6411.7044.3437.71Price / Book-0.664.225.134.73Net Income$3.21M$1.33M$118.85M$225.42M Lionheart Acquisition Co. II Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LCAPLionheart Acquisition Co. IIN/A$1.87+0.5%N/A+51.2%$34.51MN/A0.003BDSXBiodesix3.9627 of 5 stars$1.05+1.9%$3.06+191.4%-47.7%$152.74M$49.09M-2.69220Short Interest ↓AKYAAkoya Biosciences2.3448 of 5 stars$3.08+0.3%$5.43+76.3%-39.6%$152.69M$86.82M-2.6190Short Interest ↑IPHAInnate Pharma2.9997 of 5 stars$1.80+1.7%$11.50+538.9%-34.9%$150.89M$66.71M0.00220Short Interest ↓Gap UpHigh Trading VolumeSGHTSight Sciences3.8061 of 5 stars$2.92-0.3%$4.62+58.2%-34.0%$148.21M$79.54M-2.86210Analyst ForecastADAPAdaptimmune Therapeutics2.412 of 5 stars$0.58-2.2%$2.79+381.4%-30.4%$148.16M$60.28M-2.63490Short Interest ↑PBYIPuma Biotechnology4.2662 of 5 stars$2.98+0.7%$7.00+134.9%-36.2%$146.29M$235.60M6.21200Analyst RevisionPositive NewsFTLFFitLife Brands4.7789 of 5 stars$31.77+0.3%$40.00+25.9%+36.9%$146.14M$52.70M18.8020Short Interest ↓News CoverageVTYXVentyx Biosciences3.6325 of 5 stars$2.05-8.9%$10.00+387.8%-4.2%$144.96MN/A-0.8730Short Interest ↓Gap DownPVLAPalvella Therapeutics3.28 of 5 stars$12.90+3.3%$38.00+194.6%N/A$144.75M$42.81M-1.07N/APositive NewsGap UpARTVArtiva BiotherapeuticsN/A$5.95+0.3%$21.00+252.9%N/A$144.53MN/A0.0081 Related Companies and Tools Related Companies BDSX Alternatives AKYA Alternatives IPHA Alternatives SGHT Alternatives ADAP Alternatives PBYI Alternatives FTLF Alternatives VTYX Alternatives PVLA Alternatives ARTV Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LCAP) was last updated on 1/31/2025 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored#1 Crypto of 2025Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lionheart Acquisition Co. II Please log in to your account or sign up in order to add this asset to your watchlist. Share Lionheart Acquisition Co. II With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
